The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
about
P1343
TRKing down an old oncogene in a new era of targeted therapyDetecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation SequencingSensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerTracking Down Response and Resistance to TRK Inhibitors.KAOS: a new automated computational method for the identification of overexpressed genes.Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerNTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.Detecting and targetting oncogenic fusion proteins in the genomic era.Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.ALK-rearranged renal cell carcinomas in children.The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.ROS1 fusions in cancer: a review.The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition.Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Infantile NTRK-associated Mesenchymal Tumors.Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity.Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells.The target landscape of clinical kinase drugs.ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.Neurotrophin Trk Receptors: New Targets for Cancer Therapy.Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer.Inhibiting TRK Proteins in Clinical Cancer Therapy.Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastomaSimultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study
P2860
Q28254287-381210D0-FD95-48AA-89D2-4EFBE9EC3D80Q30489158-46B2A7A9-F97A-4F03-A73B-DEF6F5CA1404Q34501536-2C48BA41-1109-4A19-880A-D38F07D8DC6AQ35889315-3D649663-53F2-479A-9EF0-6AF0BB10D25EQ36276385-8DB6CE00-1D6C-4BA2-8A1C-F5C92E0EEBE8Q36432094-211A396B-C4E4-4640-850F-5EF9A40EB94BQ36629492-A8B92526-AE6B-4E60-8C12-B7B33A9D9236Q38336067-E03EB9A8-463D-4F28-8263-3F1522396ED2Q38604854-DA440ADF-87B6-4CFF-9801-0E25466CE38EQ38698507-57639F35-E5F8-43E7-85FB-99ED03255932Q38735300-7B9E0157-F646-4C68-965A-6CF5BDB5660CQ38794338-949E539D-77BC-4CF4-85BB-62C7D0FB0088Q38852070-0982C8A5-6CBD-4002-9D71-AE44FABF2310Q38880745-6218B485-9193-45C7-B5C8-0E9FE0822FC1Q38943518-FFD3DAE4-810E-4CA8-A466-D00475409AA2Q39166808-21F8AB5D-02C3-4495-8184-6B0E45F646AEQ41093124-2DA63E03-0F85-4916-9C7C-C4B0F80BF8B0Q41548672-B2C123F5-8111-4371-9731-ACFE6EBD7E6CQ41636361-24EC7D5B-F5C3-492E-B486-43F2F113A265Q46044924-9C90B6CE-7215-49AC-A670-831438557ED9Q46173337-412FA1D9-CEC7-4432-B6E7-28576E931D6CQ47301095-01273DDD-8534-4CDC-B77F-8C2C5BE864A3Q47345032-5457FD89-2EC3-4B25-8BE5-29660A0A379CQ49691234-A96629BB-4DA8-475C-B029-F566BFDB4CB3Q50201584-DD6366E6-8DA8-458A-B98F-C2618FF559D0Q53071733-4E2CE4EB-DF76-46BA-AF67-B3E70157F1C0Q54117764-560DBD01-A287-4D3B-AD30-2B33038607B9Q54981810-D37E8244-E4E3-44F3-A0F4-45192FCDD258Q55424463-F4EB2007-0576-42BD-9529-019B3DC50AD0Q58698690-7C98CEAC-A16B-4990-85C3-47908B1EE871Q58774174-B01DA3BB-B82C-49A8-89A6-14E38ED3D390
P2860
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The TPM3-NTRK1 rearrangement i ...... ity to TRKA kinase inhibition.
@en
type
label
The TPM3-NTRK1 rearrangement i ...... ity to TRKA kinase inhibition.
@en
prefLabel
The TPM3-NTRK1 rearrangement i ...... ity to TRKA kinase inhibition.
@en
P2093
P2860
P50
P1433
P1476
The TPM3-NTRK1 rearrangement i ...... vity to TRKA kinase inhibition
@en
P2093
Alessio Somaschini
Andrea Lombardi Borgia
Andrea Milani
Antonella Isacchi
Arturo Galvani
Cristina De Ponti
Daniele Casero
Daniele Donati
Dario Ballinari
Eduard Felder
P2860
P304
P356
10.1016/J.MOLONC.2014.06.001
P577
2014-06-12T00:00:00Z